Alberta adds Alyftrek coverage for cystic fibrosis patients aged six and older
Alberta’s new listing covers eligible patients aged six and older, including some with mutations that do not qualify for Trikafta.
In this article & details
Alberta announced public drug coverage for Alyftrek on Nov. 13, adding another option for eligible residents aged six and older with cystic fibrosis. The province said some patients whose mutations do not qualify for treatment with Trikafta can receive the newly listed medicine.
The addition brings the number of cystic fibrosis drugs on the Alberta Drug Benefit List to four, according to the province. More than 600 Albertans have cystic fibrosis; that figure describes the provincial population with the disease, beyond the group eligible for the new drug.
Coverage extends to some patients who lack a modulator option
Alyftrek combines vanzacaftor, tezacaftor and deutivacaftor in a once-daily medicine. The three ingredients act on the cystic fibrosis transmembrane conductance regulator, the protein affected by the genetic changes that cause the disease. Alberta has covered Trikafta since 2021. The new listing gives some people with a different set of responsive mutations access to treatment that targets the same underlying protein.
In its reimbursement review for patients aged six and older, Canada’s Drug Agency recommended funding Alyftrek under conditions. It cited trials in patients aged 12 and older in which Alyftrek was noninferior to Trikafta for change in lung function, and more limited evidence from a single-arm study in children aged six to 11. The agency also identified uncertainty around people with mutations for which response was demonstrated only in laboratory testing. The review supports an additional option without establishing that it improves lung function more than Trikafta.
Cystic Fibrosis Canada urges other plans to follow
Kelly Grover, president and CEO of Cystic Fibrosis Canada, welcomed the announcement and called on provinces and territories that have yet to fund the drug to move quickly. The patient organization tracks access to CF modulators across the country. The Nov. 13 decision applies to eligible Albertans under the provincial drug plan.
References
- Expanding treatment options for cystic fibrosis — Government of Alberta, Coverage announcement, Nov. 13, 2026
- Alyftrek reimbursement recommendation for patients aged six and older — Canada’s Drug Agency, Reimbursement review, December 2025
- Highly effective modulators — Cystic Fibrosis Canada, Canadian access and treatment background
Discussion
0 commentsJoin the discussion. Anyone can read the comments. To comment, log in or create a free individual account.
No comments yet.